Online citations, reference lists, and bibliographies.
← Back to Search

Is Pleurectomy/Decortication Superior To Extrapleural Pneumonectomy For Patients With Malignant Pleural Mesothelioma? A Single-Institutional Experience.

T. Miyazaki, N. Yamasaki, T. Tsuchiya, K. Matsumoto, Ryotaro Kamohara, G. Hatachi, T. Nagayasu
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE This study was performed to compare the outcome of pleurectomy/decortication (P/D) with that of extrapleural pneumonectomy (EPP) for patients with malignant pleural mesothelioma (MPM). METHODS Patients with MPM underwent either P/D or EPP from August 2008 to December 2014. Various clinicopathological factors were analyzed to identify differences between the two procedures. RESULTS P/D was performed in nine patients and EPP in 30 patients. Most of the patients' background characteristics were not significantly different between the groups. The surgery time (680 vs. 586 min, p = 0.0034) and bleeding volume (4050 vs. 2110 mL, p = 0.002) were significantly greater in P/D than in EPP; however, grade ≥3 complications (44% vs. 33%, p = 0.54) and length of postoperative hospital stay (29 vs. 37 days, p = 0.26) were not significantly different. The median survival time and 2- and 3-year survival rates in all patients were 16.7 months, 28.5%, and 15.3%, respectively. The median survival time and 2- and 3-year survival in the P/D and EPP groups were 22.5 months, 43.8%, and 43.8% and 16.5 months, 24.0%, and 14.4%, respectively (p = 0.13). CONCLUSION Survival of patients with MPM remains poor despite multidisciplinary treatment. P/D is comparable with EPP and could be a safe and another surgical treatment for patients with MPM.
This paper references
10.1016/j.jtho.2016.08.147
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
A. Nowak (2016)
10.1093/ejcts/ezu514
Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer.
T. Miyazaki (2015)
10.1016/j.ejcts.2010.12.024
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
D. Sugarbaker (2011)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1093/ejcts/ezw215
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.
Maurizio Infante (2016)
10.1093/jjco/hyt035
A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma.
M. Shimokawa (2013)
10.1016/j.athoracsur.2016.06.069
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
V. Rusch (2016)
10.1016/j.jtho.2016.09.121
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
D. Rice (2016)
10.1200/JCO.2005.07.050
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
10.1016/j.jtcvs.2015.09.121
Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.
H. Batırel (2016)
10.3978/j.issn.2072-1439.2015.11.15
Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.
T. Tagawa (2015)
10.1007/s00595-015-1275-3
Current surgical strategies for malignant pleural mesothelioma
T. Takuwa (2015)
10.1016/j.jtho.2017.11.003
National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma.
Zaid M Abdelsattar (2018)
10.1200/JCO.2017.73.8401
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
D. Nelson (2017)
10.1016/j.cllc.2017.01.008
The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma
Shinkichi Takamori (2017)
10.1016/j.jtho.2016.09.123
The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation
H. Pass (2016)
10.2147/TCRM.S104077
Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?
Seda Tural Onur (2016)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1093/icvts/ivw422
Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients.
Arthur Kostron (2017)
Clinical role of a new prognostic score using platelet-to-lymphocyte Ann Thorac Cardiovasc Surg Advance Published Date: January 23, 2018 7 Miyazaki T, et al
T Tagawa (2015)
10.1200/JCO.2017.72.9012
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
F. Grosso (2017)
10.1007/s10147-015-0925-1
Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial)
S. Hasegawa (2015)
10.1007/s00595-016-1448-8
Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients
T. Miyazaki (2016)
10.1016/j.athoracsur.2014.09.056
Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.
E. Taioli (2015)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1016/j.athoracsur.2016.08.071
Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.
J. Friedberg (2017)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar